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Abstract 
 
Human mesenchymal stem cells (hMSC) are a promising cell source for several 
applications of regenerative medicine. The used cells are either autologous or 
allogenic, whereas the latter enables, especially by using of stem cell lines, a 
production of cell therapeutic or tissue engineered implants in stock. Therefore, the 
usually small initial cell number has to be increased. For that purpose bioreactors are 
demanded, which offer the controlled expansion of the hMSC under GMP-conform 
conditions.  
In this study, divided in part A and B, a fixed bed bioreactor system based on 
non-porous borosilicate glass spheres for the expansion of hMSC, demonstrated with 
the model cell line hMSC-TERT, is introduced. The system offers a comfortable 
automation of the inoculation, cultivation, and harvesting procedures. Furthermore 
the bioreactor owns a simple design which benefits the manufacturing as disposable. 
Part A is focused on the inoculation, cultivation, and harvesting procedures. 
Cultivations were performed in lab scales up to a bed volume of 300 cm3. It could be 
shown that the fixed bed system, based on 2-mm borosilicate glass spheres, as well 
as the inoculation, cultivation, and harvesting procedures are suitable for the 
expansion of hMSC with high yield and vitality. 
 
 
 
 
Key words 
mesenchymal stem cells, hMSC-TERT, fixed-bed reactor, glass carrier 
5 
 
Introduction 
Due to their multipotency, mesenchymal stem cells can differentiate into various cell 
types like chondrocytes, neurocytes, myocytes, or osteocytes [1, 2] and are thus in 
focus of medicines and researchers. Autologous as well as allogenic cells can be 
used for regenerative medicine, whereas the allogenic cells have to be encapsulated 
to protect them from the host’s immune system. However, the use of allogenic stem 
cells, especially stem cell lines, allows the production in shelf of cell therapeutic 
implants.  
The expansion of mesenchymal stem cells from the initial cell number to an 
industrial relevant scale demands a bioreactor system that provides a gentle 
cultivation and harvest of the shear sensitive cells. Furthermore, the reactor system 
should be designed as a simple device that can be manufactured as disposable. The 
thereby saved cleaning and sterilization steps benefit the implementation of the 
system in GMP-conform processes. Additional important points concern the online 
monitoring of the cultivation status and the possibility of process automation.  
A variety of bioreactor systems for the cultivation of diverse stem cell types have 
been described. It can be distinguished between static culture, often performed in cell 
culture plates or T-flasks [3-6], suspension reactors like spinner flasks [4, 7-9], stirred 
tanks or rotary bioreactors [6, 10-12], and perfusion reactors [4, 13-16]. Suspension 
and perfusion reactors require carrier or matrix systems which offer a suitable growth 
surface for the anchorage dependent cells. Cultivations of mesenchymal stem cells 
were performed, beside of T-flasks, in spinner flasks containing microcarrier 
(Cytodex® 1 and 3) [8], in rotary bioreactors [11], and in special reactors for 
stimulating the chondrogenic and osteogenic differentiation of encapsulated cells [4, 
17]. The disadvantage by using static culture systems is the large labor input due to 
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the intricate automation of the inoculation, cultivation, and harvesting procedures. A 
better automation is feasible in suspension reactors, but the harvesting procedure 
and especially the separation process of the cells from the carrier is still intricate and 
means additional devices. This drawback can be overcome by using of fixed-bed 
reactors based on non-porous carrier. The non-porosity supports the separation of 
enzymatically detached cells from the immobilized carrier by flushing them out with 
the medium flow. Fixed-bed reactors can be simple designed, that benefits the 
production as disposable. Additionally an automation and process monitoring can 
easily be realized.  
Up to now no cultivation of hMSC in fixed-bed reactors in order to expand the 
initial cell number has been described. In this work an axial fixed-bed reactor system 
for the cultivation of hMSC, which considers the requirements stated above, is 
introduced. The fixed-bed is based on non-porous borosilicate glass spheres with a 
diameter of 2 mm. These carriers are most suitable in respect to the nutrient supply 
and harvesting procedure as shown previously [18]. 
The used cells are human mesenchymal stem cells (hMSC), which are 
genetically modified with the gene of the catalytic subunit of human telomerase 
(TERT). This telomerase activity counteracts the shortening of the telomeres that 
occurs at each cleavage and thus leads to a permanent cell line [19].  
Inoculation, cultivation, and harvesting procedures, which allow the automated 
generation of hMSC-TERT with high yield and vitality, were developed. Cultivations 
were performed in three different scales up to 300 cm3 and cell densities of up to 
2.9 x 106 cells/cm3. The cultivation process was mathematically modeled in part B of 
this study. This enabled the theoretical scale up of the fixed-bed system which was 
exemplarily done for a target cell number of 20 billion. Cell dependent temporally 
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oxygen profiles were used for monitoring of the cultivation status. Growth and 
consumption kinetics were determined by fitting model parameters to the 
experimental data and in order to validate the model, from separate experiments in 6-
well cell culture plates. 
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Materials and Methods 
 
All chemicals were obtained from Sigma-Aldrich (Deisenhofen, Germany) unless 
otherwise indicated.  
The hMSC-TERT cell line was provided by the CellMed Ag (Alzenau, germany). 
The passage numbers throughout the experiments were between 65 and 85. 
All deviations resulted from repeated parallel experiments were expressed as 
standard deviation. Error propagations were considered using the Gaussian error 
propagation law. No further statistical evaluations were performed because of the 
small numbers of repeats of the cultivation runs.  
 
The fixed-bed reactor system 
The lab-scale fixed-bed reactors up to a bed volume FBV  of 60 cm3 consisted of 
commercial glass syringes with special inserts, which replaced the original pistons 
(Figure 1 a, b) [20]. This perforated funnel shaped inserts, made of PEEK, offered a 
hose connector and thus enabled the perfusion of the packed beds with a 
homogenous inflow. A second custom-made system used for the 300 cm3 scale was 
composed of a glass tube that was placed between stainless steel lid and bottom 
plates (Figure 1 c). These plates offered tube connections for the medium in- and 
outlet. A funnel shape insert for spreading of the incoming medium made up of 
stainless steel was placed in the inlet region. In both systems a stainless steel mesh 
avoided that the fixed bed enters the inlet tubing (Figure 1 a). 
The fixed-bed reactors comprised non-porous borosilicate glass spheres with a 
diameter of 2 mm. This means a volume specific growth surface /FB FBA V  of 18.3 
cm2/cm3. A preliminary carrier screening with several porous and non-porous carriers 
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has revealed, that non-porous borosilicate glass spheres of 2 mm diameter are most 
suitable in respect to growth, cell harvest, and nutrient supply [18]. 
Three flasks equipped with sterile air filters for pressure compensation were 
connected to the fixed-bed reactor and acted as conditioning, inoculum, waste, and 
collecting vessel (Figure 1 d). The waste vessel contained the inoculum prior to the 
inoculation procedure. Oxygen concentration was measured in the medium in- and 
outflow using non-invasive oxygen sensors (Fibox 3, PreSens Precision Sensing 
GmbH, Augsburg, Germany). Medium was perfused by means of a peristaltic pump 
(IPC-8, Ismatec SA, Glattbrugg, Switzerland) and directed using pinch valves (100P 
NC 24-05, msscientific GmbH, Berlin, Germany). The reactor system was operated in 
a humidified incubator at 37°C and 5% CO2. The medium was aerated in the 
conditioning vessel by surface aeration.  
 
Static cell culture of hMSC-TERT 
Cultivation in T-flasks 
Stocks were thawed in a 37°C water bath until ice crystals completely disappeared. 
Afterwards cell suspensions were diluted in culture medium, which consisted of 
Eagles Minimal Essential Medium (EMEM; Biochrom, Berlin, Germany), 
supplemented with 10% fetal calf serum (FCS; Biowest, Nuaillé, France), at room 
temperature and centrifuged at 230 x g. After decantation of the supernatants, cells 
were resuspended in fresh medium, seeded into T300-flasks at a cell density of 5000 
cells/cm2, and cultured with 75 ml medium in a humidified incubator at 37°C and 5% 
CO2 until a cell density of approximately 150,000 cells/cm2 was reached. Medium 
was exchanged after three days of cultivation. Harvesting of cells was carried out by 
adding 0.05 ml/cm2 trypsin-EDTA solution, incubation for 5 min, and rinsing of the 
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flasks with medium to stop the enzymatic reaction. Cells were used for experiments 
or subcultivated in T300-flasks after centrifugation and resuspension in medium.  
 
Determination of growth and glucose consumption kinetics in 6-well cell culture 
plates 
A Monod kinetic limitation by glucose was assumed. For determination of the 
dependency of the growth rate and glucose consumption rate on the glucose 
concentration four 6-well cell culture plates were inoculated with 5000 cell/cm2 and 
cultured with 1 ml medium per well for eight days. Three wells were harvested daily 
and the cell numbers as well as the glucose concentrations were determined. The 
growth rate at each time interval  
 
 ( )1j j jt t t −∆ = −    j = 1, 2, 3 … n  
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This equation is only valid for the log phase of the cell growth, which was determined 
by taking the logarithm of the growth curve.  
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the surface A , 
 
the glucose concentration Glcc , and  the medium volume V . 
The growth and consumption rates were plotted versus the logarithmic mean of the 
glucose concentration ,
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by curve fitting.  
 
Dynamic cell culture of hMSC-TERT in the fixed bed systems 
Inoculation procedure  
The inoculation procedure was performed in different ways. In the first method a 
14.2 cm3 fixed bed was filled with cell suspension (10,000 cells per cm2 growth 
surface area) and incubated for 90 min without perfusion. This method was then 
modified in order to return settled non-adhered cells into the fixed bed and thus 
increase the yield of adherent cells. For it the fixed bed was perfused for 7 min at a 
superficial velocity v
 
of 1.2 x 10-4 m s-1 after time intervals of 30 min. This cycle was 
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repeated two or four times, so that the overall durations of these inoculation 
procedures were 104 and 178 min. The perfusion time was calculated from the fixed 
bed height FBh , the superficial velocity v , and the factor 1.1, which means an overlap 
of the cell suspension over the fixed bed of 10%: 
 
1.1 FBperf
ht
v
= ⋅
     
Equation 5 
 
During the 30-min phases without perfusion the valve V1 (Figure 1 c) was closed to 
avoid a sedimentation of cells into the tubing. After the inoculation procedure, the 
fixed bed was rinsed with medium so as to get rid of non-adherent cells. The fixed 
beds were removed in layers to represent the axial cell density distribution. For 
determination of the cell number, nuclei were counted using a Neubauer 
hematocytometer after lysis of the cells with citric acid and staining with crystal violet 
as previously described [21]. The experiments were performed in triplicates.   
 
Influence of the superficial velocity on the growth rate 
Due to the non-porosity of the carrier, the cells are totally exposed to shear stress 
caused by the medium flow. This demands a determination of an upper limit for the 
superficial velocity v , which is important for an up-scaling of the process (see part B 
of this publication). The used criterion is the point at which the mean growth rate mµ  
starts to decrease.  
The investigations were carried out in four parallel-operated 14.2 cm3 fixed-bed 
reactors. For that, fixed beds were inoculated as described above with 1.83 x 105 
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cells/cm3 (104 cells/cm2) and cultivated at three different superficial velocities v . For 
more details of these cultivations see Table 1.  After cultivation, the fixed beds were 
removed in layers to represent the axial cell density distribution. Cell densities were 
determined by crystal violet staining of the nuclei at the end of the cultivations [21]. 
The mean growth rates were calculated according to Equation 1.  
 
Cultivation in different fixed bed scales  
Additional to the cultivation in 14.2 cm3 fixed-bed reactors as described above, 
cultivations in a 60 cm3 and 300 cm3 scale were performed. The reactors were 
inoculated with 1.3 x 105 cells/cm3 (7 x 103 cells/cm2) and 1.8 x 105 cells/cm3 (10 x 
103 cells/cm2), respectively, but it has to be noted, that this was not the initial cell 
density since only 50% of the inoculated cells got attached to the carrier as it will be 
shown subsequently. More details to the cultivations are given in Table 1. Cell 
densities were calculated from the oxygen consumption and determined by counting 
of the nuclei after cell lysis and crystal violet staining.  
The cell numbers jXN
 
at the time points jt  were calculated using the oxygen 
concentration difference between the in- and outlet , ,
j j
Ox in Ox outc c− , the oxygen 
consumption rate Oxq  as well as the volume flow rate V :  
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Equation 6
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For simplification, the oxygen uptake kinetic was considered as independent from the 
concentration and calculated with the oxygen difference between the medium in- and 
outlet at the end of the fixed bed cultivation:   
 
( ), ,n nOx CV Ox FB
Ox n
X
c s V
q
N
− ⋅
=

    Equation 7 
 
n
XN  is the cell number counted at the end of cultivation, ,
n
Ox CVc  is the associated 
oxygen concentrations in the conditioning vessel and thus in the inlet of the fixed bed 
and ,
n
Ox FBc  the outlet concentration.  
From the cell densities jFBX , calculated with the cell number 
j
XN  and the fixed-
bed volume FBV , the initial cell density 
0
FBX  and the mean growth rate mµ
 
were 
obtained by curve fitting:  
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The mean glucose consumption rate ,Glc mq  was calculated by the following equation 
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,
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with the medium volume in the conditioning vessel CVV , the cultivation duration nt , 
and the log mean of the cell density  
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Harvesting procedure 
Investigations for the cell harvesting were performed in 14.2 cm3 fixed-bed reactors 
at a cell density AX  of about 10
5 cells/cm2. AccutaseTM was mainly chosen because 
it is less harmful to the cells compared to trypsin. The investigated methods can be 
divided in two classes:  
1. The enzyme solution and with it the detached cells were cyclic perfused with a 
comparably high superficial velocity v .  
2. The enzyme solution was perfused at lower velocity and directly led to the 
collecting vessel. Then the detached cells were flushed out by means of 
perfusion of the fixed bed with medium at higher velocity, which was directed 
to the collecting vessel too. 
The second procedure is assumed to be more gently because of the avoided 
recirculation of detached cells which causes less shear stress. More details to the 
harvesting experiments are given in Table 2. In order to avoid inhibiting effects of the 
serum to the enzyme activity the fixed beds were rinsed with 100 ml PBS in each 
case prior to enzymatic treatment.   
Evaluation criteria for the harvesting procedures were the yield, which is defined 
as the number of detached cells to the overall cell number in the fixed bed, and the 
vitality, that is defined as the ratio of living cells to the total number of detached cells. 
Vitality was measured with the trypan blue exclusion method.  
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 Results and Discussion 
 
Growth and glucose uptake kinetics in 6-well cell culture plates 
The glucose dependent growth and glucose consumption kinetics in static culture 
were obtained by fitting of Equation 3 and Equation 4 to the growth or consumption 
rate versus glucose concentration curves (Figure 2 and Figure 3). The maximal 
growth rate maxµ  and the Monod constant , GlcM µK  were found to be 0.66 ± 0.02 d
-1 
and 0.14 ± 0.03 mg ml-1. The maximal glucose uptake rate ,maxGlcq  was 
(7.7 ± 1.1) x 10-8 mg h-1 cell-1 with the according Monod constant , GlcM qK  = 
0.16 ± 0.06 mg ml-1.  
It was assumed, that glucose is the limiting medium component. This assumption 
is corroborated by the fact, that the curve in Figure 3 passes the origin of the 
coordinates. A limitation by other nutrients like glutamine would shift the intersection 
with the x-coordinate. In addition, glutamine has been reported to be an unimportant 
energy source for human, goat, and rat mesenchymal stem cells [22]. 
The relation of lactate to consumed glucose is 2.74 mol/mol. This points at an 
inefficient metabolism of glucose for energy mainly via glycolysis. As well Schop et al. 
(2009) reported a high lactate/glucose ratio of up to 2.13 mol/mol at the cultivation of 
hMSC [22].  
An oxygen limitation during the cultivation in cell culture plates can be excluded 
because of the high surface area to cell number relation. An estimation of the oxygen 
saturation of the medium at the highest cell density of 6.3 x 104 cells cm-2 using an 
oxygen transfer coefficient of 0.184 m h-1 [23] and an oxygen consumption rate of 2 x 
10-8 mg h-1 cell-1 leads to an saturation of about 99 %. Assuming a higher oxygen 
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consumption rate of 4 x 10-8 mg h-1 cell-1 would only reduce the oxygen saturation to 
about 97 %. 
Table 3 and Table 4 give some examples of published growth and glucose 
consumption kinetics of several animal and human cells or cell lines. The kinetics 
determined in this work are in the same range of those reported values.  
 
Cultivation in fixed-bed reactors 
Inoculation procedure 
The yield of adherent cells after the inoculation procedure could have been increased 
by repeated perfusion of the fixed bed from 35 %, without perfusion, to 49% (Figure 
4). No tendency dependent on the inoculation strategy regarding to the axial cell 
distribution could be detected.  
Additional perfusion steps, another superficial velocities v , or time intervals 
between the perfusion steps could lead to a further enhancement of the yield of 
adherent cells. Thus, continuative studies are recommended. 
 
Influence of the superficial velocity on the growth rate 
The mean growth rate mµ  in the exponential phase decreases from 0.62 ± 0.01 d-1 at 
a superficial velocity v  of 2.65 x 10-4 m s-1 to 0.29 ± 0.01 d-1 at a superficial velocity of 
1.59 x 10-3 m s-1 (Figure 5). A flow velocity dependent trend in axial cell distribution 
could not be observed. 
A mean growth rate mµ  of 0.62 d-1 is close to the maximal growth rate maxµ  of 
0.66 d-1, determined in static culture in 6-well cell culture plates, which can only be 
reached by an infinite glucose concentration because of the Monod kinetic. Therefore 
it may be assumed, that a further decrease of superficial velocity v  would not lead to 
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a significant increase in growth rate. For all of the subsequently performed 
cultivations, the rounded superficial velocity v  of 3.0 x 10-4 m s-1 was used.  
 
Cultivation of hMSC-TERT at different fixed bed scales 
hMSC-TERT were cultured in scales FBV  of 14, 60, and 300 cm3. Figure 6 to Figure 8 
show the experimental data. The results are summarized in Table 5. 
The cells were cultured up to a density nFBX  of (2.93 ± 0.11) x 106 cells/cm3. 
Higher cell densities are not recommendable because of the risk of channeling and 
drawbacks by up-scaling of the fixed bed system, as shown in part B of this 
publication. The initial cell densities 0FBX  and 
0
AX  were about 50 to 60% of the 
inoculated cell densities that confirms the results of the inoculation procedure.  
The mean growth rate mµ  and the oxygen consumption rate Oxq  decreased with 
advancing passage number from 0.60 to 0.42 d-1 and 2,03 x 10-8 to 1,08 x 10-8 
mg h-1 cell-1, respectively, whereas the mean glucose consumption rate ,mGlcq  
increased  from 7,65 x 10-8 to 9,50 x 10-8 mg h-1 cell-1. Although hMSC-TERT are 
considered as a permanent cell line, changes in growth and consumption kinetics 
occur within 17 passages. A decrease of growth rate with advancing passage 
number has been reported for other cells like hMSC or adipose stem cells (rhesus 
monkey) [24, 25]. A consequence of this is that an optimized process design is only 
valid for a closed range of passage numbers.  
All kinetics are within the range of those reported for several animal and human 
cells or cell lines (Table 3, Table 4, and Table 6).  
For the oxygen uptake a zero order kinetic was assumed. This assumption is 
valid for an oxygen saturation above 20% and thus for the performed cultivation runs 
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[26]. Furthermore in part B of this study the constants of the growth kinetic maxµ  and 
, GlcM µ
K  were determined by fitting model parameters to the experimental data of the 
fixed-bed cultivations [27]. Comparing the constants of the cultivation in the 14 cm3 
scale (passage number = 68) to those of the cultivation in 6-well cell culture plates 
(passage number = 69) of this publication no remarkable deviation in , GlcM µK  
occurred. This suggests that the oxygen saturation has at least in the range of 35% 
to 100% a negligible effect on the growth kinetic. Otherwise the observable Monod  
constant , GlcM µK for the glucose dependence of the growth rate would be wrongly 
increased.  
 
Harvesting procedure 
Increasing of the superficial velocity v  of the cyclic perfused AccutaseTM solution 
from 8.0 x 10-4 to 3.2 x 10-3 m s-1 and extension of the residence time from 10 to 20 
min enhanced the yield from 5% to 76% (Figure 9, procedure a-c; Table 2). The 
vitality was 84%. Better results were obtained with non-cyclic perfusion of the 
enzyme solution and flushing out of the cells by a short time perfusion of the fixed 
bed with a comparably high superficial velocity (Figure 9, procedure d-i; Table 2). 
Treatment of the cells with AccutaseTM solution for 10 min and a superficial velocity v  
of 1.8 x 10-4 m s-1 followed by perfusion with medium for 2 min and a superficial 
velocity of 3.2 x 10-3 m s-1 resulted in a yield of (82.1 ± 2.3)% and a vitality of (96.5 ± 
0.7)%. Altogether, non-cyclic perfusion led to higher vitalities compared to cyclic 
perfusion, which is explainable by the reduced shear stress due to non-repeated 
passage of already detached cells through the system components.  
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Conclusion 
The introduced fixed-bed reactor concept based on non-porous borosilicate glass 
spheres is suitable for the cultivation of hMSC-TERT. An application of the system for 
the cultivation of non-modified hMSC is supposable.  
The introduced inoculation, cultivation, and harvesting procedures are designed 
for an automated performance of hMSC-TERT expansion with high yield and vitality 
of the harvested cells.   
The simple designed reactor, which includes in principle a carrier filled tube 
connected to a conditioning vessel, enables a production of this system as 
disposable. An easy automation and a comfortable process monitoring by measuring 
of the oxygen concentration at the inlet and outlet or glucose concentration in the 
conditioning vessel, for example, benefit the transfer of this system into a GMP-
process.  
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Nomenclature  
 
A  growth surface [m2] 
FBA  overall growth surface of the fixed bed [m2] 
Glcc  glucose concentration [kg m-3] 
0
Glcc  initial glucose concentration [kg m-3] 
n
Glcc  glucose concentration at the end of the cultivation (time point 
nt ) [kg m3] 
,Glc CVc  glucose concentration in the conditioning vessel [kg m-3] 
,
jt
Glc mc
∆  logarithmic mean of the glucose concentration in the time interval jt∆  [kg m-3] 
,Lac CVc lactate concentration in the conditioning vessel [kg m-3] 
*
Oxc  maximal dissolved oxygen [kg m
-3] 
,Ox CVc  oxygen concentration in the conditioning vessel (fixed-bed inlet) [%] 
,Ox FBc  oxygen concentration in the fixed-bed outlet [%] 
FBh  fixed bed height [m] 
,M µK  Monod constant for the growth kinetic [kg m-3] 
, GlcM q
K Monod constant for the glucose consumption kinetic [kg m-3] 
XN  cell number [-] 
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j
XN  cell number at the time point jt  [-] 
n
XN  cell number at the end of cultivation (time point nt ) [-] 
Glcq  glucose consumption rate [kg s-1 cell-1]  
j
Glc
tq∆  glucose consumption rate in the time interval jt∆  [kg s-1 cell-1] 
,mGlcq  mean glucose consumption rate [kg s
-1 cell-1] 
,maxGlcq maximal glucose consumption rate [kg s-1 cell-1] 
Oxq  oxygen consumption rate [kg s-1 cell-1]  
,Ox CVs  oxygen saturation in the conditioning vessel (fixed-bed inlet) [%] 
,Ox FBs  oxygen saturation in the fixed-bed outlet [%] 
perft  time of perfusion [s] 
v  superficial velocity [m s-1] 
V  volume [m3] 
V  flow rate [m3 s-1] 
FBV  fixed bed volume [m3] 
CVV  medium volume (conditioning vessel) [m3] 
AX  area related cell density [m-2] 
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,
jt
A mX
∆  logarithmic mean of the area related cell density in the time interval jt∆  [m-2] 
FBX  volume related cell density [m-3] 
n
FBX  cell density at the end of cultivation [m-3]  
,
jt
FB mX
∆  logarithmic mean of the volume related cell density in the time interval jt∆   
[m-3] 
 
 
 
jt∆  time interval 1j jt t −−    j = 1, 2, 3 … n  
µ  growth rate [s-1] 
mµ  mean growth rate [s-1] 
maxµ  maximal growth rate [s-1] 
jtµ∆   growth rate in the time interval jt∆  [s-1] 
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Legends 
Figure 1: Fixed bed bioreactor systems for the expansion of hMSC-TERT. 
a) Custom made insert for enabling the usage of commercial available syringes 
as fixed bed bioreactors 
b) Syringe based small-scale fixed-bed reactor filled with 2 mm borosilicate glass 
spheres 
c) Fixed bed bioreactor in a up to 500-cm3 scale filled with 2-mm borosilicate 
glass spheres 
d) Scheme of the bioreactor periphery 
 
Figure 2:  Monod kinetic of the growth rate (medium volume per well = 1.0 ml). The 
data represents the mean ± standard deviation (SD) of triplicates.   
 
Figure 3:  Monod kinetic of the glucose consumption rate (medium volume per well = 
1.0 ml). The data represents the mean ± standard deviation (SD) of triplicates.  
 
Figure 4:  Yield of adherent cells and axial cell density distribution obtained by 
application of different inoculation procedures. Perfusion steps with a superficial 
velocity v  of 1.2 x 10-4 m s-1 were applied for 7 min in time intervals of 30 min. The 
data represents the mean ± standard deviation of triplicates.  
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Figure 5:  Axial cell density distributions and mean growth rates mµ  after six days of 
cultivation of hMSC-TERT in 14.2-cm3 fixed-bed reactors at different superficial 
velocities v . The fixed beds consisted of 2 mm borosilicate glass spheres. The data 
represent the mean ± SD of three cultivations in each case.   
 
Figure 6:  Experimental data of a hMSC-TERT cultivation in four parallel operated 
fixed-bed reactors with a volume of each 14.2 cm
3. The reactors were connected to 
one conditioning vessel. Oxygen saturation was measured in the in and outlet of only 
one fixed-bed reactor. The data point of the counted cell number represents the 
mean ± SD of the four reactors. The reactors were perfused with a superficial velocity 
v  of 2.7 x 10-4 m s-1. The conditioning vessel contained 1000 ml EMEM + 10% FCS. 
 
Figure 7:  Experimental data of a hMSC-TERT cultivation in a 60-cm3 fixed-bed 
reactor. The reactors were perfused with a superficial velocity v  of 3.0 x 10-4 m s-1. 
The conditioning vessel contained 500 ml EMEM + 10% FCS. 
 
Figure 8:  Experimental data of a hMSC-TERT cultivation in a fixed-bed reactor with a 
volume of 300 cm3. The conditioning vessel contained 4800 ml EMEM + 10% FCS. 
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Figure 9:  Yield and vitality of hMSC-TERT obtained with different harvesting 
procedures.   
n: number of trials, et : duration of perfusion with the enzyme solution, mt : duration of 
perfusion with the medium, ev : superficial velocity during incubation with the enzyme 
solution, mv : superficial velocity during the perfusion with medium  
a) AccutaseTM; ev  = 8.0 x 10-4 m s-1; et  = 10 min; n = 1 
b) AccutaseTM; ev  = 1.6 x 10-3 m s-1; et  = 10 min; n = 1 
c) AccutaseTM; ev   = 3.2 x 10-3 m s-1; et  = 20 min; n = 1 
d) AccutaseTM; ev   = 1.8 x 10-4 m s-1; mv  = 1.6 x 10-3 m s-1; et   = 10 min; 
mt  = 1 min; n = 3  
e) AccutaseTM; ev   = 1.8 x 10-4 m s-1; mv  = 1.6 x 10-3 m s-1; et   = 10 min; 
mt  = 2 min; n = 2 
f) AccutaseTM; ev   = 1.8 x 10-4 m s-1; mv  = 3.2 x 10-3 m s-1, et   = 10 min; 
mt  = 1 min; n = 2 
g) AccutaseTM; ev   = 1.8 x 10-4 m s-1; mv  = 3.2 x 10-3 m s-1; et   = 10 min; 
mt  = 2 min; n = 2 
h) AccutaseTM/trypsin; ev  = 1.8 x 10-4 m s-1; mv  = 1.6 x 10-3 m s-1; et  = 10 
min; mt  = 2 min; n = 2 
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i) AccutaseTM/trypsin; ev  = 1.8 x 10-4 m s-1; mv  = 3.2 x 10-3 m s-1; et  = 10 
min; mt  = 2 min; n = 3 
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Tables 
 
Table 1: Performed hMSC-TERT cultivations in fixed-bed bioreactors at different 
scales. Bold-faced cultivations were used for the model verification in part B of this 
study.  
Fixed-bed 
volume  
FBV  [cm3] 
Growth 
surface 
FBA  
[cm2] 
Inoculated 
cell 
density  
[cm-2] 
Medium 
volume 
CVV  [ml] 
Superficial 
velocity v  
[m s-1] 
Medium 
changes  
[h] 
Cultivation 
time  
[h] 
4 x 14.2 4 x 260 10,000 1,000 2.65 x 10-4 115 135 
4 x 14.2 4 x 260 10,000 1,000 7.96 x 10-4 93 134 
4 x 14.2 4 x 260 10,000 1,000 15.92 x 10-4 105 138 
60 1098 7,000 500 3.0 x 10-4 - 168 
300 5490 10,000 4,800 
(0.8 - 3.3) x 
10-4 
 149 167 
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Table 2: Overview of the harvesting experiments performed in fixed-bed reactors at a 
scale of 14.2 cm3. A: AccutaseTM solution, T: trypsin solution (0.25% in PBS without 
calcium and magnesium) 
Enzyme 
Superficial 
velocity, 
enzyme 
solution ev   
[m s-1] 
Duration of 
perfusion 
with the 
enzyme 
solution  
et   [min] 
Superficial 
velocity, 
medium mv  
[m s-1] 
Duration of 
perfusion 
with 
medium 
mt   [min] 
Method 
A 8.00 x 10-4  10 - - cyclic perfusion 
of enzyme 
solution 
A 1.58 x 10-3 10 - - 
A 3.18 x 10-3 20 - - 
A 1.83 x 10-4  10 1.58 x 10-3 1 non-cyclic  
perfusion of 
enzyme solution 
and medium 
(directly led to 
the collecting 
vessel) 
A 1.83 x 10-4 10 1.58 x 10-3 2 
A 1.83 x 10-4  10 3.17 x 10-3 1 
A 1.83 x 10-4  10 3.17 x 10-3 2 
A+T* 1.83 x 10-4  10 1.58 x 10-3 2 
A+T* 1.83 x 10-4  10 3.17 x 10-3 2 
*1:1 v/v 
 
 
 
 
36 
 
Table 3: Published growth kinetics of several cell types. 
Cell type Growth rate [d-1] 
Monod  
constant 
[mg ml-1] 
Reference 
Adipose stem cells (rhesus 
monkey) 
0.37 (passage 11)                
0.23 (passage 14) 
- [24] 
Mesenchymal stem cells (human) 0.66 - 0.94 - [28] 
Mesenchymal stem cells (human) 0.5 - [29] 
Mesenchymal stem cells (human) 0.55 - [30] 
Myeloma cell line X63-Ag8.653 
(murine) 
1.56 0.13 [31] 
Mesodermal progenitor cells 
(human) 
0.33 - 1.3 - [32] 
Embryoicl stem cell line H9 
(human) 
0.47 - [33] 
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Table 4: Published glucose consumption kinetics of several cell types. 
Cell type 
Glucose consumption 
rate [mg -1 h-1 cell-1] 
Monod 
constant 
[mg ml-1] 
Referen
ce 
Embryonic stem cell line S25 
(murine) 
(0.9 - 1.88) x 10-8 - [7] 
Mesenchymal stem cells (human) (2.25 - 6.9) x 10-8 - [28] 
CHO (hamster) 8.46 x 10-8 - [34] 
Hybridoma  cell line 4C10B6 
(murine) 
(0.13 - 1.37) x 10-7 - [35] 
Mesenchymal stem cells (human) 1.22 x 10-7 - [36] 
Leucemic cell line K562 (human) 1.59 x 10-7 - [37] 
Vero (Chlorocebus) 2.4 x 10-8 0.1 [38] 
 
 
 
 
 
 
 
 
 Table 5: Results of the  hMSC-TERT cultivation in 2-mm borosilicate glass spheres comprising fixed-bed reactors.  
  Units FBV  = 4 x 14.2 cm
3 FBV  = 60 cm
3 FBV  = 300 cm
3 
Cultivation time [h] 135 168 167,3 
End cell density nFBX  
[cm-2]            
[cm-3] 
(1.60 ± 0.06) x 105  
(2.93 ± 0.11) x 106  
9.56 x 104  
1.75 x 106  
1.12 x 105  
 2.05 x 106 
Passage number - 68 71 84 
Superficial velocity v  [m s-1] 2.7 x 10-4 3.0 x 10-4 (0.8 - 3.3) x 10-4 
Lactate/glucose  
[mg/mg]   
[mol/mol] 
1.61 
3.22 
0.80  
1.60 
0.93 
1.86 
Initial cell density * 0AX   and 
0
FBX  
[cm-2]             
[cm-3] 
(5.64 ± 0.50) x 103          
(1.03 ± 0.09) x 104  
(3.68 ± 0.99) x 103        
(6.63 ± 1.81) x 104  
(6.39 ± 0.66) x 103    
(1.17 ± 0.12) x 105         
Mean growth  rate * mµ  [d-1] 0.60 ± 0.02 0.49 ± 0.04 0.42 ± 0.02 
Mean glucose consumption rate * ,mGlcq  [mg h-1 cell-1] (7.65 ±  0.3) x 10-8 (6.80 ± 0.43) x 10-8 (9.50 ± 0.27) x 10-8 
* Correlation coefficient  [-] 0.999 0.998 0.924 
 Oxygen consumption rate Oxq  
 
[mg h-1 cell-1] 2.03 x 10-8 2.06 x 10-8 1.08 x 10-8 
 Table 6: Published oxygen consumption kinetics of several cell types. 
Cell type 
Oxygen consumption 
rate [mg h-1 cell-1] 
Monod constant  
[mg ml] 
Reference 
Adherent mononuclear cells 
from bone marrow (human) 
(1.22 ± 0,19) x 10-8 - [39] 
Skin fibroblasts (rat) 1.88 x 10-8 2.0 x 10-4  [40] 
Hematopoietic stem cells 
(human) 
1.92 x 10-8 - [41] 
Breast cancer stem cells 
(human) 
(3.2 ± 0,07) x 10-8 (2.3 ± 0.5) x 10-3 [42] 
Hybridoma cell line 4H11 
(murine-human) 
1.1 x 10-8 - [43] 
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